GlassScriptPhysician profile
Syed A Rizwan
NPI 1881665735
$2,515.63
in general payments reported to CMS, 2019-2025
29 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $224 · 2021: $113 · 2022: $79.57 · 2023: $139 · 2024: $731 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,684.67 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $425.71 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $271.01 | 2020-2025 | Farxiga, Lokelma |
| Amgen INC. | $183.44 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $175.15 | 2019-2024 | Veltassa |
| Alexion Pharmaceuticals, INC. | $173.66 | 2019-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $144.42 | 2020-2025 | Acthar |
| Ardelyx, INC. | $129.49 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.07 | 2024-2025 | Jardiance |
| Genentech USA, INC. | $115.77 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $93.84 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $68.17 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $57.95 | 2024-2025 | Rayaldee |
| Akebia Therapeutics INC | $57.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $52.07 | 2019 | |
| Alnylam Pharmaceuticals INC. | $50.46 | 2019-2024 | Givlaari |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $49.23 | 2024 | Defencath |
| Otsuka America Pharmaceutical, INC. | $49.21 | 2020-2025 | Voyxact |
| Recor Medical INC | $44.53 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Kyowa Kirin, INC. | $39.28 | 2025 | |
| Travere Therapeutics, INC. | $27.66 | 2023-2024 | |
| Horizon Therapeutics Plc | $25.97 | 2023 | Krystexxa |
| Novo Nordisk INC | $24.56 | 2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $23.91 | 2025 | |
| Scpharmaceuticals INC. | $23.04 | 2025 | |
| Ani Pharmaceuticals, INC. | $19.91 | 2022 | |
| Apellis Pharmaceuticals, INC. | $16.80 | 2025 | Empaveli |
| Glaxosmithkline, LLC. | $16.26 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.56 | 2025 | |
| Chiesi USA, INC. | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rizwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.